Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02433236

Enrollment

Registered

2015-05-04

Start date

2015-09-30

Completion date

Unknown

Last updated

2015-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IGA Nephropathy

Brief summary

Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.

Interventions

DRUGFostamatinib Disodium tablet 100 mg

DRUGFostamatinib Disodium tablet 150 mg

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 72 Years

Healthy volunteers

Inclusion criteria

* Completed Study C-938788-050, including having received a post-treatment renal biopsy, and having had a clinically meaningful response (i.e. decreased proteinuria or improved renal histology) * Able and willing to give written informed consent

Exclusion criteria

* Unresolved Grade 2 or greater toxicity in Study C-935788-050

Design outcomes

Primary

Measure	Time frame
Number of Participants with mean change of Proteinuria as measured by spot urine protein/creatinine ratio (sPCR)	15 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026